Financial Planning Hawaii Inc. Invests $605,000 in Eli Lilly and Company $LLY

Financial Planning Hawaii Inc. bought a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 563 shares of the company’s stock, valued at approximately $605,000.

A number of other large investors have also added to or reduced their stakes in LLY. Kieckhefer Group LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth $269,000. Orrstown Financial Services Inc. boosted its position in Eli Lilly and Company by 9.2% in the 4th quarter. Orrstown Financial Services Inc. now owns 1,538 shares of the company’s stock valued at $1,653,000 after buying an additional 130 shares during the last quarter. Harrell Investment Partners LLC boosted its position in Eli Lilly and Company by 11.1% in the 4th quarter. Harrell Investment Partners LLC now owns 652 shares of the company’s stock valued at $701,000 after buying an additional 65 shares during the last quarter. Northstar Advisory Group LLC grew its stake in shares of Eli Lilly and Company by 121.4% during the fourth quarter. Northstar Advisory Group LLC now owns 4,678 shares of the company’s stock valued at $5,027,000 after acquiring an additional 2,565 shares in the last quarter. Finally, J. Safra Sarasin Holding AG increased its position in shares of Eli Lilly and Company by 17.2% during the fourth quarter. J. Safra Sarasin Holding AG now owns 82,328 shares of the company’s stock worth $88,478,000 after acquiring an additional 12,069 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Daiwa Securities Group increased their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Barclays began coverage on Eli Lilly and Company in a report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price objective on the stock. The Goldman Sachs Group set a $1,260.00 target price on Eli Lilly and Company in a research report on Thursday, February 5th. Bank of America reduced their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.26.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approved Lilly’s oral GLP‑1 weight‑loss pill Foundayo — the approval opens a large, fast‑growing obesity market for a convenient daily pill (Lilly will sell Foundayo via LillyDirect with low listed cash prices and broad availability), which drove the stock rally. Lilly’s weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk – reuters.com
• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals (up to ~$7.8B including milestones) to add orexin/OX2R sleep‑wake assets — diversification into neuroscience reduces concentration risk on GLP‑1s and supports longer‑term growth expectations. Eli Lilly to buy Centessa Pharma in $6.3 billion deal – Reuters
• Positive Sentiment: Unusual bullish options flow — large volume of call buying suggests traders positioned for further upside after the approval/announcements, amplifying intraday momentum. Eli Lilly Pops on GLP‑1 Pill Approval. Should You Buy LLY Stock Here? – Barchart
• Neutral Sentiment: Competitive dynamics — Novo Nordisk is responding with subscription pricing for Wegovy and other tactics; Foundayo’s pricing/coverage and real‑world adoption vs. Wegovy will determine market share, so near‑term upside could be capped by competition. Novo Nordisk (NVO) Stock: New Wegovy Subscription Pricing Takes on Eli Lilly – Blockonomi
• Negative Sentiment: Policy and pricing risk — Lilly’s CEO publicly opposed codifying ‘Most Favored Nations’ drug‑pricing deals into law, highlighting ongoing regulatory/political risks that could pressure pricing or margins over time. Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO says – CNBC

Eli Lilly and Company Stock Up 3.9%

NYSE:LLY opened at $955.45 on Thursday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The company has a market capitalization of $902.73 billion, a price-to-earnings ratio of 41.63, a price-to-earnings-growth ratio of 1.07 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The stock has a 50-day simple moving average of $999.28 and a 200 day simple moving average of $966.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the prior year, the firm posted $5.32 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.